Follow-up study of twenty-four families with Li-Fraumeni syndrome
- PMID: 1933872
Follow-up study of twenty-four families with Li-Fraumeni syndrome
Abstract
The Li-Fraumeni cancer family syndrome is manifested by susceptibility to breast cancer, sarcomas, and other neoplasms in children and young adults. The present study utilized clinical follow-up data on 545 members of 24 Li-Fraumeni kindreds living and cancer-free at family ascertainment. Two hypotheses were tested based on a model of autosomal dominant genetic predisposition: (a) that syndrome cancers would continue to occur excessively during follow-up compared to the general population, and (b) that the tumors would occur primarily among those family members likely to carry the gene. Population cancer rates were compared with cancer rates in follow-up of the cohort from ascertainment to 1988. Risk of carrying the gene for the syndrome at the time of ascertainment was calculated for each family member under two models with somewhat different definitions of affection with the syndrome. Cancer occurrence after ascertainment was then analyzed according to the risks. Cancer did continue to occur excessively among the entire cohort during follow-up [relative risk (RR 2.1)]. The excess was greatest below age 20 (RR 21.1), declined with increasing age, and was most pronounced for neoplasms featured in the syndrome (RR 18.2). Among persons less than age 45, at least 87% of cancers occurred in those at higher risk of carrying the gene under both genetic models (RR 22.9 and 21.3). The clinical data, therefore, reliably identify individuals likely to carry a dominantly inherited gene conferring susceptibility to a specific constellation of neoplasms. Recent identification of a germ line mutation in the tumor suppressor gene p53 in persons with the syndrome may, if confirmed, have implications for ultimately defining the component tumors of the syndrome and for the causes and prevention of those tumors arising outside these families.
Similar articles
-
[Li-Fraumeni syndrome].Bull Cancer. 1997 Jul;84(7):735-40. Bull Cancer. 1997. PMID: 9339200 Review. French.
-
Cancer risks from germ line tumor suppressor gene mutations.Princess Takamatsu Symp. 1991;22:61-70. Princess Takamatsu Symp. 1991. PMID: 1844252 Review.
-
The Li-Fraumeni syndrome: an inherited susceptibility to cancer.Mol Med Today. 1997 Sep;3(9):390-5. doi: 10.1016/S1357-4310(97)01105-2. Mol Med Today. 1997. PMID: 9302689 Review.
-
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.Oncogene. 1998 Sep 3;17(9):1061-8. doi: 10.1038/sj.onc.1202033. Oncogene. 1998. PMID: 9764816
-
[Li-Fraumeni syndrome and the p53 gene].Tidsskr Nor Laegeforen. 1992 Mar 10;112(7):887-9. Tidsskr Nor Laegeforen. 1992. PMID: 1557756 Review. Norwegian.
Cited by
-
Timing and context: important considerations in the return of genetic results to research participants.J Community Genet. 2016 Jan;7(1):11-20. doi: 10.1007/s12687-015-0231-7. Epub 2015 May 26. J Community Genet. 2016. PMID: 26004130 Free PMC article.
-
Gastric cancer in individuals with Li-Fraumeni syndrome.Genet Med. 2011 Jul;13(7):651-7. doi: 10.1097/GIM.0b013e31821628b6. Genet Med. 2011. PMID: 21552135 Free PMC article.
-
Tumor suppressor genes in molecular medicine.Clin Investig. 1994 Aug;72(8):619-30. doi: 10.1007/BF00227456. Clin Investig. 1994. PMID: 7819720 Review. No abstract available.
-
Variation of breast cancer risk among BRCA1/2 carriers.JAMA. 2008 Jan 9;299(2):194-201. doi: 10.1001/jama.2007.55-a. JAMA. 2008. PMID: 18182601 Free PMC article.
-
Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium.Int J Epidemiol. 2020 Feb 1;49(1):216-232. doi: 10.1093/ije/dyz193. Int J Epidemiol. 2020. PMID: 31605532 Free PMC article.
MeSH terms
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous